Form 4: ResMed Director Harjit Gill Acquires 1,083 Shares Through Restricted Stock Units

ResMed director Harjit Gill acquired 1,083 shares of common stock through the vesting of restricted stock units.

Summary

• ResMed director Harjit Gill acquired 1,083 shares of ResMed common stock on November 20, 2024.
• The shares were acquired through the vesting of restricted stock units (RSUs).
• The RSUs cliff vest on the earlier of November 11, 2025, or the annual shareholder's meeting in the year following the grant date.
• Following the transaction, Mr. Gill directly owns 9,905 shares of ResMed common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to director compensation and is common for publicly traded companies.

Comparison to Industry Standards

• The use of restricted stock units as part of director compensation is a standard practice in publicly traded companies.
• Many companies in the medical device industry use similar equity-based compensation plans to align the interests of directors with those of shareholders.
• The vesting schedule of the RSUs is also typical, with vesting often tied to time or performance milestones.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates director confidence in the company.

Key Dates

Keywords

ResMed, Director, Harjit Gill, Restricted Stock Units, RSU, Share Acquisition, Beneficial Ownership, SEC Form 4